Navigation Links
Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
Date:12/7/2007

ruggling with cocaine addiction will be treated in the future. We believe that the success of the trial provides scientific proof of concept. We are highly encouraged by the top-line results and look forward to publication of the results in a peer-reviewed journal. Catalyst will also evaluate the methodology and results for their potential applicability to our ongoing U.S. Phase II trial evaluating CPP-109 for the treatment of cocaine addiction and to our planned U.S. Phase II trial evaluating CPP-109 for the treatment of methamphetamine addiction."

About The Trial

This trial is the third in a series of human trials conducted in Mexico, which successfully tested the safety and efficacy of vigabatrin to treat cocaine and/or methamphetamine addiction. These trials followed more than 15 years of animal studies conducted by Dr. Stephen Dewey at Brookhaven National Laboratory. All three human trials were conducted under the direction of Dr. Jonathan Brodie, the Marvin Stern Professor of Psychiatry at the New York University (NYU) School of Medicine and Dr. Emilia Figueroa, Director of the Clinica Integral de Tratamiento Contra las Adicciones, S.A. de C.V. The first two trials were small open-label studies. The trial's protocol was approved by NYU's Institutional Review Board in May 2006 and the Federal Commission for Sanitary Risks Protection (Mexico) in September 2006 and is registered at http://www.clinicaltrials.gov with the identifier NCT00527683. Catalyst provided financial support through an unrestricted gift to NYU.

One hundred and three community-based, non-hospitalized cocaine addicted individuals participated in this investigator-initiated, randomized, double- blind, placebo-controlled trial conducted at a single site in Mexico City. All subjects had ready access to cocaine and were self-motivated to stop their use. The trial was designed to show whether vigabatrin treatment could si
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
11. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... has found that India,s shocking rates of suicide are ... are clinging to tiny smallholdings less than one ... as cotton and coffee, that are highly susceptible to ... of previous case studies that point to a crisis ... ,liberalisation, of the nation,s economy during the 90s. Researchers ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
(Date:4/17/2014)... that lost its status as the leading weapon against ... of life, with new research indicating it simply needs ... the use of the cheap anti-malarial drug chloroquine in ... lives of more than half a million people each ... malaria has developed resistance to chloroquine, but research carried ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today ... CDX-1401 in solid tumors, including long-term patient follow-up, have ... 6 Issue 232). The data demonstrate robust antibody and ... patients with very advanced cancers and suggest that CDX-1401 ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... ... new book “A must have...The Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian ... (PRWEB) May 6, ... new inspiration with the release of “A must have...The Maroema Cook Book” by Mamta Reid. ...
... heart disease and stroke rates in China will rise ... aging population and other increased risk factors, without policies ... smoking, according to research from Columbia University Medical Center ... an American Heart Association journal. "China,s standard of ...
... events , WEDNESDAY, May 5 (HealthDay News) -- A ... significantly cuts down on hospital drug errors, researchers from ... "We had the opportunity to design and implement a ... the hospital gets the right medication at the right ...
... Researchers at the University of Toronto have discovered a ... number of genes to generate enormously complex organs such as ... in the journal Nature entitled "Deciphering the Splicing ... Benjamin Blencowe of the University of Toronto describes how a ...
... Nausea in pregnant women tends to fade after the ... it can be a sign of flu, researchers at UT ... women who sought medical care. "People don,t necessarily think ... vomiting, but our study showed that they are common with ...
... finds , WEDNESDAY, May 5 (HealthDay News) -- People who,ve ... face an increased risk for heart complications and death if ... study has found. , "We looked at the risks connected ... Nicholas L.M. Cruden, a former cardiology lecturer at the University ...
Cached Medicine News:Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 2Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 3Health News:Bar Codes Cut Down on Hospital Medication Errors 2Health News:Bar Codes Cut Down on Hospital Medication Errors 3Health News:U of T researchers crack 'splicing code,' solve a mystery underlying biological complexity 2Health News:Nausea and speeding heart can be signs of flu in pregnant women 2Health News:Risks Rise for Other Surgeries After Stent Implants 2
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... YORK, Oct. 17, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0487169/Novo-Nordisk-A/S-PharmaVitae-Profile.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... the historical and forecast performance for Novo ...
... Inc. (NASDAQ: ANDS ) today announced that it has ... (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger ... outstanding shares of common stock of Anadys at USD 3.70 per ... represents a 256% premium over the closing price of USD 1.04 ...
Cached Medicine Technology:Novo Nordisk A/S: PharmaVitae Profile 2Anadys Announces Agreement To Be Acquired By Roche 2Anadys Announces Agreement To Be Acquired By Roche 3Anadys Announces Agreement To Be Acquired By Roche 4
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: